Carbamazepine and L-type calcium channel inhibitors: a binding assay study.
Ngan
E T
ET
Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Vincent
S R
SR
D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics*; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000493:pharmacokinetics*; D004110:Diltiazem / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D017275:Isradipine / Q000493:pharmacokinetics; D008094:Lithium / Q000494:pharmacology; D008297:Male; D010627:Phenethylamines / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D014700:Verapamil / Q000493:pharmacokinetics
D018712:Analgesics, Non-Narcotic; D002121:Calcium Channel Blockers; D010627:Phenethylamines; C041094:N,N-bis(3,4-dimethoxyphenethyl)-N-methylamine; D002220:Carbamazepine; D008094:Lithium; D014700:Verapamil; D004110:Diltiazem; D017275:Isradipine